



Cyclooxygenase inhibitory compounds from *Gymnosporia heterophylla* aerial parts



Charles O. Ochieng^{a,*}, Sylvia A. Opiyo^a, Edward W. Mureka^a, Ismail O. Ishola^b

^a Department of Chemistry, Maseno University, Private Bag, 40105, Maseno, Kenya

^b Department of Pharmacology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, P.M.B. 12003 Lagos, Nigeria

ARTICLE INFO

Keywords:

Gymnosporia heterophylla

Celastraceae

Dihydroagarofuran sesquiterpene alkaloids

Triterpenes

COX inhibitions

ABSTRACT

Gymnosporia heterophylla (Celastraceae) is an African medicinal plants used to treat painful and inflammatory diseases with partial scientific validation. Solvent extractions followed by repeated chromatographic purification of the *G. heterophylla* aerial parts led to the isolation of one new β -dihydroagarofuran sesquiterpene alkaloid (1), and two triterpenes (2–3). In addition, eight known compounds including one β -dihydroagarofuran sesquiterpene alkaloid (4), and six triterpenes (5–10) were isolated. All structures were determined through extensive analysis of the NMR and MS data as well as by comparison with literature data. These compounds were evaluated for the anti-inflammatory activities against COX-1 and -2 inhibitory potentials. Most of the compound isolated showed non selective COX inhibitions except for 3-Acetoxy-1 β -hydroxyLupe-20(29)-ene (5), Lup-20(29)-ene-1 β ,3 β -diol (6) which showed COX-2 selective inhibition at 0.54 (1.85), and 0.45 (2.22) IC₅₀, in mM (Selective Index), respectively. The results confirmed the presence of anti-inflammatory compounds in *G. heterophylla* which are important indicators for development of complementary medicine for inflammatory reactions; however, few could be useful as selective COX-2 inhibitor.

1. Introduction

Inflammatory complications are as serious causes of morbidity and limitation of physical activity, especially in the elderly [1]. Although there is no cure, medications including steroids, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are commonly used for the management of inflammatory disorders. Since most of these drugs are associated with undesirable side effects such as gastrointestinal disturbances [2], complementary and alternative anti-inflammatory drugs are needed [3]. NSAIDs are well known as COX inhibitors, which are markedly up regulated at the inflammatory sites [3], opening the possibility for discovering selective inhibitors with reduced gastrointestinal side effects.

The plants of the genus *Gymnosporia* (syn. to *Maytenus*) are widely used in folk medicine as an antiseptic, antiasthmatic, fertility regulating agent, antitumor, as well as for stomach problems [4]. The genus *Gymnosporia* are notably used in Brazilian traditional medicine for the treatment of gastric ulcers [5], inflammation and diarrhea [6] as antimicrobial [7], and antitumor [8]. In south-central Zimbabwe, *G. buxifolia* is particularly used as a remedy for abdominal pains and the aerial parts reported for antiplasmodial and anti-inflammatory activities [9]. Similarly, *G. heterophylla* and *G. senegalensis* are two African

medicinal plants used to manage painful and inflammatory diseases [10], a claim confirmed through an *in vivo* experiment using leaf extracts of the two plants on mice that showed a significant anti-inflammatory activity [10]. *G. heterophylla* is further claimed by different African communities to be used against malaria [11]; sexually transmitted diseases (antimicrobial effects); breathing difficulties and chest pains [12]; in the management of livestock diarrhea [13]; and eradication of ticks from animals [14]. Phytochemical studies on the plant *G. heterophylla* reported the isolations of a dihydroagarofuran alkaloid, heterophyllin together with β -amyryn, 3 α -hydroxy-2-oxofriedelane-20 α -carboxylic acid, lupeol, lup-20(29)-ene-1 β ,3 β -diol, (–)-4'-methylepigallocatechin and (–) epicatechin from EtOH extracts of the aerial parts [15]. Pristimerin isolated from *G. heterophylla* stem bark showed potent anticytomegalovirus properties against human cytomegalovirus (HCMV) [16] whereas maytenfolic acid showed moderate antimicrobial activity [15].

In vivo anti-inflammatory activities of ethanol leaf extracts *G. heterophylla* and *G. senegalensis* were evaluated against carrageenan-induced paw oedema in Wistar albino rats, which indicated significant anti-inflammatory activity of up to 35% and 51% oedema reductions, respectively [10]. However, while *G. heterophylla* extracts at 1200 mg/kg showed no toxicity, *G. senegalensis* extracts indicated some toxicity.

* Corresponding author.

E-mail addresses: otieno.charles9@gmail.com, cochieng@maseno.ac.ke (C.O. Ochieng).

Such results indicated significant safe anti-inflammatory effects of *G. heterophylla* against acute inflammation and suggested the absence of acute and sub-acute toxicity signs of the *G. heterophylla* leaf extract [10]. Since anti-inflammatory activities of the compounds from *G. heterophylla* responsible for such activities remained uncertain, establishment of medicinal efficacies of the plant were thus partial. The present study was undertaken to investigate COX inhibitory potential of the compounds from aerial parts the plant to contribute to an understanding of their possible mechanism in treatment of inflammatory disorders.

2. Experimental

2.1. General instrumentation

Optical rotations were measured on a Perkin-Elmer 341 polarimeter. UV spectra were measured using CHCl₃ on a Perkin-Elmer Lambda 25 UV/Vis spectrophotometer. IR spectra were recorded as glassy film of KBr on Perkin Elmer 200 FT-IR spectrometer. The HRTOF-MS spectra were recorded on Finnigan Mat SSQ 7000 direct probe mass spectrometer. ¹H NMR (400 MHz), ¹³C NMR (100 MHz) spectra were recorded on Bruker's Avance-400 FT 400 MHz using deuterated solvents and referenced to residual TMS signal. Silica gel ((Merck Keisegel 60, 0.063–0.200 mm) used for gravity column chromatography together with analytical thin layer chromatography on Merck 60 F₂₅₄ (0.25 mm) plates, which were visualized by UV inspection and/or spraying with 5% H₂SO₄ in EtOH and/or 4% anisaldehyde-sulphuric acid reagent, followed by heating at 110 °C for 10 min.

2.2. Plant materials

The leaves and stem bark of *G. heterophylla* were collected in April 2015 from Kitale KCC forest (1°01'27.14"N 35°00'55.04"E) Trans Nzoia County in western Kenya and authenticated in the National Museum of Kenya where the voucher specimen (MEW/03/2014) was deposited.

2.3. Solvent extraction

The air-dried and crushed aerial parts of *G. heterophylla* (2.6 kg) were extracted three times with MeOH (64 l) at room temperature (20–26 °C) for 24 h. A dark brown residue was obtained after removing the solvent under reduced pressure, which was suspended in H₂O, and then partitioned with *n*-hexane, EtOAc and *n*-butanol to yield 2.2 g, 23.6 g, 11.6 g and 21.6 g, respectively. The EtOAc-soluble extract (150.0 g) was chromatographed over a silica gel column and eluted with *n*-hexane-CH₂Cl₂ (100:0–0:100, v/v) followed by CH₂Cl₂-MeOH (100:0–5:95, v/v) to give thirteen fractions (Fr. 1–Fr. 6). Fractions 1–4 yielded 3-hydroxycamphane (7) (71 mg) [3,4-seco-olean-3,11β-olide (8)] (35 mg), and lupeol (9), respectively as white amorphous compounds after recrystallization in CH₂Cl₂-MeOH. Further column chromatographic separation on fraction 5 (3.74 g) followed by preparative TLC yielded 3-Acetoxy-1β-hydroxyLupe-20(29)-ene (5) (64 mg), 2-Methoxy-4-deoxyzeylasterone (3) (96 mg) and pristimerin (10) (34 mg). Further separation of fraction 6 (3.4 g) on silica gel column chromatography followed by fractional recrystallization of the two major eluates yielded lup-20(29)-ene-1β,3β-diol (7) (21 mg, R_f 0.35) and 3,4-seco-1-hydroxy-21-oxo-olean-3, 11-olide (2) (83 mg).

The *n*-butanol extract showed positive results for presence of alkaloids with Dregendoff reagents which prompted extraction of alkaloids. The methanol extract (20 g) was dissolved in H₂O and acidified with H₂SO₄ to pH 3–4, then extracted with petroleum ether to remove acidic and neutral compounds which on drying yielded 8.5 g (alkaloid-free extracts). The aqueous solution was further basified to pH 9–10 with NH₄OH (25% ml/ml) followed by dichloromethane extraction. The extract was washed with distilled water, dried with anhydrous Na₂SO₄ followed with concentration to dryness under

Table 1
¹H (400 MHz) and ¹³C (100 MHz) NMR data of compound 1 (CDCl₃).

| Atom | δ _H (multiplicity, J, Hz) | δ _C (ppm) |
|----------------------|--------------------------------------|----------------------|
| 1 | 5.60 d (4) | 76.3 |
| 2 | 4.83 m | 69.4 |
| 3 | 1.60 m/1.92 m | 22.2 |
| 4 | 2.25 m | 36.8 |
| 5 | – | 88.1 |
| 6 | 5.94 s | 76.7 |
| 7 | 2.23 dd (4.3, 3) | 48.2 |
| 8 | 2.28 m/2.56 m | 31.0 |
| 9 | 5.68 d (6.8) | 76.4 |
| 10 | – | 51.5 |
| 11 | – | 81.5 |
| 12 | 1.57 s | 25.0 |
| 13 | 1.56 s | 26.7 |
| 14 | 1.16 d (8) | 20.7 |
| 15 | 1.24 s | 17.2 |
| 1-OC=O | – | 170.5 |
| 1-O=CCH ₃ | 2.02 s | 20.8 |
| 2-OC=O | – | 169.9 |
| 2-O=CCH ₃ | 1.95 s | 22.3 |
| 6-OC=O | – | 165.9 |
| 2' | 9.43 s | 153.6 |
| 3' | – | 123.8 |
| 4' | 8.84 d (7) | 137.4 |
| 5' | 7.58 d (7.2) | 128.7 |
| 6' | 8.57 d(7.2) | 155.6 |
| 9-OC=O | – | 165.3 |
| 1 | – | 129.1 |
| 2'6' | 8.17 d (8.8) | 130.4 |
| 3'5' | 7.45 d (8) | 128.7 |
| 4' | 7.55 dd (8, 8) | 133.3 |

Assignments were aided by 2D NMR COSY, HMQC and HMBC experiments.

reduced pressure using a rotatory evaporator to afforded 9.3 g crude alkaloid extracts. The alkaloid extracts (8 g) which showed two spots on TLC was separated by column chromatography on silica gel (50 g, activated grade) in *n*-hexane-dichloroethane-dichloromethane-5% methanol-dichloromethane. 1β,2β-diacetoxy-9β-benzoyloxy-6α-nicotinoyloxy-β-dihydroagarofuran (1) (100 mg) was obtained from the dichloromethane (100%) eluent after crystallization from dichloromethane-*n*-hexane mixture (1:1). Elution with 2% methanol in dichloromethane furnished 1β-acetoxy-9β-benzoyloxy-4α-hydroxy-6α-nicotinoyloxy-β-agarofuran (4), (81 mg) after recrystallization.

2.4. Physical and spectroscopic data of isolated of compounds from *G. heterophylla* stem bark

Compound 1 (1β,2β-diacetoxy-9β-benzoyloxy-6α-nicotinoyloxy-β-dihydroagarofuran) white crystalline solids. Mp. 130–132 °C; [α]_D + 73.0° (c, 1.00, CHCl₃); UV λ_{max} (log_e) (CHCl₃): 270 (3.94), 260 (3.62), 229 (3.90) nm; IR (KBr) ν cm⁻¹: 1759, 1721, 1611, 1459, 1039, 715; ¹H NMR and ¹³C NMR (CDCl₃, 400 MHz and 100 MHz; Table 1); HRTOFMS: (*m/z*) 602.7435. (C₃₂H₃₇NO₉Na) [M + Na]⁺.

Compound 2 (3,4-seco-1-hydroxy-21-oxo-olean-3, 11-olide): white amorphous solid, m.p 268–270 °C; IR (KBr) ν cm⁻¹: 2990, 1740, 1371, 1277, 1248 cm⁻¹. ¹H NMR and ¹³C NMR (CDCl₃, 400 MHz and 100 MHz; Tables 2 and 3); ESIMS *m/z* 470.68 (M⁺).

Compound 3 (2-Methoxy-4-deoxyzeylasterone): pale yellow amorphous solid, m.p 252–254 °C. TLC (purple spot R_f1.6) Uncorrected; IR (KBr) ν cm⁻¹: 3400, 2900, 1742, 1721, 1642, 1298 and 717 cm⁻¹. UV (MeOH) λ_{max}: 241 nm and 304 nm; ¹H NMR and ¹³C NMR (CDCl₃, 400 MHz and 100 MHz; Tables 2 and 3); HRESIMS *m/z* (482.4196 [M]⁺, 505.4316 [M + Na]⁺).

2.5. Cyclooxygenase inhibitory assay

Inhibitory activities of the compounds towards COX-1 and COX-2

Table 2
¹H NMR (400 MHz) and ¹³C NMR (100 MHz) data for compounds **2**, and **3** (CDCl₃).

| Atom | 2 δ _H ppm, multiplicity (J) | δ _C (ppm) | 3 δ _H ppm, multiplicity (J) | δ _C (ppm) |
|--------------------|---|----------------------|---|----------------------|
| 1 | 4.34 dd (4.8, 7.9) | 79.6 | 6.82 s | 109.5 |
| 2α | 3.19 dd (7.9, 14.5) | 44.5 | | 150.8 |
| 2β | 2.79 dd (4.8, 14.5) | | | |
| 3 | – | 172.4 | | 152.8 |
| 4 | 2.75 m | 56.0 | 7.61 s | 113.2 |
| 5 | 2.05 m | 85.0 | | 141.9 |
| 6α | 1.69 m | 33.2 | | 201.2 |
| 6β | 2.13 dt (3.5, 13.8) | | | |
| 7α | 1.59 | 27.6 | 2.53 dd (17, 3) | 43.8 |
| 7β | 1.16 t (6.6) | | 2.14 dd (12, 17) | |
| 8 | – | 43.2 | 2.38 dd (3, 12) | 35.4 |
| 9 | 2.03 d (9.2) | 55.2 | | 38.6 |
| 10 | | 44.5 | | 123.5 |
| 11 | 4.54 d (9.2) | 67.3 | 1.36 dt (5, 13) | 32.4 |
| | | | 2.18 dt (4, 14) | |
| 12 | 5.76 d (2.9) | 133.5 | 1.43 dt (5, 12) | 29.9 |
| | | | 1.99 dt (3, 11) | |
| 13 | | 139.8 | | 36.8 |
| 14 | | 42.6 | | 35.9 |
| 15α | 1.57 m | 19.8 | 1.58 m | 30.3 |
| 15β | 1.56 m | | 1.62 m | |
| 16α | 1.55 m | 34.1 | 1.43 m | |
| 16β | 1.43 m | | 1.56 m | |
| 17 | – | 51.4 | – | 35.7 |
| 18 | 1.60 t (3.5) | 37.8 | 1.86 t (6) | 40.4 |
| 19α | 1.65 dd (3.5, 14.6) | 40.5 | 1.46 d (6) | 29.5 |
| 19β | 1.48 dd (7.2, 14.6) | | 1.58 d (6) | |
| 20 | | 47.7 | | 39.1 |
| 21α | – | 215.9 | 1.47 dt (4, 11) | 29.6 |
| 21β | – | | 1.24 dt (5, 13) | |
| 22α | 2.36 d (14.5) | 40.4 | 1.19 dt (4, 12) | 28.2 |
| 22β | 3.01 d (14.5) | | 1.39 dt (5, 13) | |
| 23 | 1.01 d (6.8) | 21.0 | 1.08 s | 31.9 |
| 24 | 1.13 d (6.7) | 20.3 | 1.02 s | 25.3 |
| 25 | 1.30 s | 13.8 | 0.78 s | 16.7 |
| 26 | 1.07 s | 19.1 | 0.99 s | 15.2 |
| 27 | 1.22 s | 22.6 | 1.16 s | 31.5 |
| 28 | 1.45 s | 26.8 | – | 179.4 |
| 29 | 1.19 s | 28.4 | | |
| 30 | 1.23 s | 21.3 | | |
| OCH ₃ | | | 3.87 s | 55.7 |
| COOCH ₃ | | | 3.62 s | 51.5 |

Assignments were aided by 2D NMR COSY, HMQC and HMBC for ¹H NMR and experiments DEPT, HMQC and HMBC for ¹³C NMR.

Table 3

Inhibitory activities of isolated compounds from *Gymnosporia heterophylla* on COX assay.

| Compound | (% Inhibitions ^a) | | IC ₅₀ (mM) ^b | | SI |
|---|-------------------------------|---------------|------------------------------------|--------------|------|
| | COX-1 | COX-2 | COX-1 | COX-2 | |
| 1β,2β-Diacetoxy-9α-benzoyloxy-6α-nicotinoyloxy-β-dihydroagarofuran (1) | 60.58 ± 4.90* | 52.23 ± 7.56* | 0.65 ± 0.02 | 0.56 ± 0.09* | 1.16 |
| 1α-Acetoxy-9α-benzoyloxy-4α-hydroxy-6α-nicotinoyloxy-β-agarafuran (4) | 55.95 ± 4.21 | 60.16 ± 6.25* | 0.58 ± 0.02 | 0.51 ± 0.02* | 1.14 |
| 3, 4- <i>seco</i> - 1-Hydroxy-21-oxo-olean-3, 11-olide (2) | 63.35 ± 6.50* | 49.72 ± 9.06 | 0.46 ± 0.07* | 0.46 ± 0.02* | 1 |
| 2-Methoxy-4-deoxyzeylasterone (3) | 29.92 ± 7.14 | 43.06 ± 8.52 | 0.61 ± 0.04 | 0.66 ± 0.02 | 0.92 |
| 3-Acetoxy-1β-hydroxyLupe-20(29)-ene (5) | 27.63 ± 7.01 | 50.62 ± 5.57 | > 1 | 0.54 ± 0.02 | 1.85 |
| Lup-20(29)-ene-1β,3β-diol (6) | 25.13 ± 5.55 | 54.64 ± 5.63* | > 1 | 0.45 ± 0.04* | 2.22 |
| 3-Hydroxycampane (7) | 30.08 ± 4.89 | 33.98 ± 4.07 | > 1 | > 1 | – |
| 3,4- <i>seco</i> -Olean-3,11β-olide (8) | 64.96 ± 5.91* | 43.85 ± 5.11 | 0.53 ± 0.07* | 0.65 ± 0.04 | 0.82 |
| Lupeol (9) | 25.82 ± 6.44 | 35.03 ± 5.40 | > 1 | > 1 | – |
| Pristimerin (10) | 64.33 ± 5.45* | 54.44 ± 6.54* | 0.48 ± 0.04* | 0.43 ± 0.03* | 1.12 |
| Aspirin | 65.27 ± 4.00 | | 0.41 ± 0.04 | > 1 | 0.41 |
| Celecoxib | | 67 ± 3.31 | > 1 | 0.43 ± 0.08 | 2.32 |

^a Inhibition (%) values were tested at 10 mM and expressed as the mean S.D. (n = 3).

^b IC₅₀ values are the mean S.D. (n = 3). Meaning the 50% inhibition concentration calculated from regression using four different concentrations (1.0, 0.5, 0.25, 0.125 mM). Values with (*) are statistically similar to the respective positive controls (P < 0.05). SI (selectivity Index) = IC₅₀ (COX-1)/IC₅₀ (COX-2) SI > 1 are selective to COX-2.

activity was determined using colorimetric COX (ovine) inhibitor screening assay kit (Cayman, No. 760111) following manufacturer's instructions. The assay was conducted by monitoring the appearance of oxidized *N,N,N',N'*-tetramethyl-phenylenediamine (TMPD) at 590 nm. Aspirin and Celecoxib served as positive controls. The test compounds were dissolved in 1% DMSO (v/v) in distilled water make up a 10 mM concentration for each compound. The same stock solution was serially diluted into four different concentrations (1.0, 0.5, 0.25 and 0.125 mM) that were used to estimate the IC₅₀ for each compound. The colorimetric substrate solution TMPD (20 μl) was added to all of the wells containing graded concentration of the compounds followed by addition of 20 μl of arachidonic acid. The plate was shaken for a few seconds and incubated for 5 min at 25 °C. The absorbance was measured at 590 nm using a microplate reader. Average absorbance was calculated for all the samples (n = 3) in order to determine the percentage of inhibition.

2.6. Statistical analysis

Results of COX inhibition activity were expressed as the mean standard error of mean (SEM). Data analyzed by using one way ANOVA followed by Turkey's multiple comparison as post-hoc test. The limit of statistical significance was set at P < 0.05.

3. Results and discussion

Repeated column chromatography on the extract of *G. heterophylla* stem bark yield a dihydroagarofuran sesquiterpene alkaloids [1β,2β-diacetoxy-9β-benzoyloxy-6α-nicotinoyloxy-β-dihydroagarofuran (**1**) and], and two triterpenes [3,4-*seco*- 1-hydroxy-21-oxo-olean-3, 11-olide (**2**) and 2-Methoxy-4-deoxyzeylasterone (**3**)] together with seven known compounds (Fig. 1). The molecular identity of the known compounds were established based on comparison of physical (mp and [α]_D) and their ¹H and ¹³C NMR data with those previously reported information as 1α-acetoxy-9β-benzoyloxy-4α-hydroxy-6α-nicotinoyloxy-β-agarofuran (**4**) [17], 3-Acetoxy-1β-hydroxyLupe-20(29)-ene (**5**) [18], Lup-20(29)-ene-1β,3β-diol (**6**) [19], 3-hydroxycampane (**7**) [20], 3,4-*seco*-olean-3,11β-olide (**8**) [21], lupeol (**9**) [22–24], and Pristimerin (**10**) [16].

Compound **1** was isolated as a crystalline solid analyzed for [C₃₂H₃₇NO₉Na] based on *m/z* 602.7435 by HRTOFMS. ¹H NMR and ¹³C NMR (Tables 1) spectra suggested the presence of a nicotinoyl, a benzoyl and an acetyl ester groups alongside six methyls including two acetyl methyls, three methylenes, four oxygenated methines, three quaternary, eleven aromatic and four ester carbonyl carbons. The ¹H




Fig. 1. Compounds isolated from the aerial parts of *Gymnosporia heterophylla*.

NMR signals observed at δ_{H} 5.94 (1H, br s), 5.68 (1H, d, $J = 6.8$ Hz), 5.60 (1H, d, $J = 4$ Hz) and 4.83 (1H, m) were assigned to the four protons attached to the carbons bearing secondary esters which were almost identical with those of 1 β -acetoxo-9 β -benzoyloxy-2 β ,6 α -dinicotinoyloxy- β -dihydroagarofuran except for the absence of a second nicotinoyl esters [15]. Thus compound 1 was deduced as 1,2,6,9-tetraesterified dihydro- β -agarofuran sesquiterpene alkaloid whose proton and carbon signal were confirmed by the ^1H - ^1H COSY and HMBC spectra (Fig. 2), which established correlations between δ_{H} 5.60 for H-1 and δ_{C} 170.5 (1-OC=O) which in turn correlated with methyl signal at δ_{H} 2.02 and another 2J correlation to δ_{C} 69.4 (C-2). Proton on C-2 was assigned as δ_{H} 4.83 based on its COSY correlation with methylene at δ_{H} 1.60 and 1.92 (H-3), which in turn coupled with a methine proton (δ_{H} 2.25, H-4) that coupled with a secondary methyl group (δ_{H} 1.16, Me-14). This proton (H-1) similarly showed 3J correlation to another carbonyl carbon at δ_{C} 169.9 (OC = O) which in turn correlated with methyl ester protons (δ_{H} 1.95) and a 2J correlation to (δ_{C} 76.3, C-1). Generally, in this class of compounds ring B is characterized by an axially configured H-6 which always appears as a singlet [25] and in

this particular compound such as singlet showed long range correlation with C-5, C-6, C-8, C-10, and C-11. Overall relative configuration was established based on the NOESY (Fig. 2) spectra which displayed strong cross peaks which showed cross peaks between H-9 and H-15 and between H-6 and H-14/H-15, indicating that H-6 and H-9 are axial and equatorial, respectively. Based on the forgoing facts and compassion of the data with that of heterophylline previously isolated from the leaves of the same plant, compound 1 was identified 1 β ,2 β -diacetoxo-9 β -benzoyloxy-6 α -nicotinoyloxy- β -dihydroagarofuran.

Compound (2) was analyzed for molecular formula $\text{C}_{30}\text{H}_{46}\text{O}_4$ based on the HRTOFMS m/z 493.2536 (calcd. for 493.2543 [$\text{M} + \text{Na}$] $^+$). The ^{13}C -DEPT-135° (Table 3) spectrum revealed the presence of thirty carbon atoms including eight methyls, seven methylenes and seven methines. Existence of eight methyl peaks suggested a pentacyclic triterpene [26] with two hydroxyl and a vinylic moiety revealed by the ^1H NMR (Table 2) signals [δ_{H} 4.34 (1H, dd, $J = 4.8, 7.9$ Hz) and 4.54 (1H, d, $J = 9.2$ Hz)] and δ_{H} 5.76 (1H, d, $J = 2.9$ Hz), respectively. Contrary to ^1H NMR signals for triterpenes compound 3 displayed a unique pair of doublets for methyl groups at δ_{H} 1.01 (3H, d, $J = 6.8$ Hz)




Fig. 2. (A) Main ^1H - ^{13}C long-range correlation HMBC (\rightarrow) and ^1H - ^1H correlation COSY ($-$) and (B) NOESY correlation (\rightarrow) for compound 1.

and 1.13 (3H, d, $J = 6.7$ Hz) both coupled to a multiplet for the methine at δ_{H} 2.75 (1H, m) and in turn showed mutually HMBC (Fig. 3) correlations indicating the presence of two geminal methyl groups to an aliphatic chain. The above spectral data indicated that compound 2 highly resembled 3,4-*seco*-friedelan-3,11 β -olide [21] expect for the presence of an oxymethine proton δ_{H} 4.34 showing HMBC correlation to δ_{C} 172.4 (C-3 lactone carbonyl) in 2. Moreover, HMBC correlation of methylene protons on C-2 [δ_{H} 3.19 (dd, $J = 14.5, 7.9$ Hz) and 2.79 (dd, $J = 14.5, 4.8$ Hz)] to carbonyl C-3 at δ_{C} 172.4 which in turn showed 3J correlation with proton on C-11 (δ_{H} 4.54 d) indicated the presence of a C-CH(OH)-CH₂-CO-O-CH a lactone moiety cyclising with an hydroxyl group at C-11 forming an ϵ -caprolactone. The location of the ketone (δ_{H} 216.1) was determined based on its HMBC correlation with two methyl groups C-29 and C-30 [δ_{H} 1.19 s, 1.23 s] and lack of HMBC correlation with H-18 confirmed the ketone functionality at C-21 not C-19. Following the observed spectroscopic evidence, the structure of compound 2 was established as in Fig. 1. The relative stereochemistry was deduced by the NOESY correlations corroborated by the biosynthetic pathway of *seco*-oleanolide. Compound 2 was thus established as 3,4-*seco*-1-hydroxy-21-oxo-olean-3,11 β -olide.

Compound (3) assigned a molecular formula C₃₀H₄₂O₅ based on ^1H and ^{13}C NMR (Tables 2 and 3, respectively) and HRTOFMS observed at m/z at 482.4196. Its IR (KBr) showed bands at 1742 cm⁻¹ (Ester carbonyl), 1621 cm⁻¹ (α, β - unsaturated carbonyl), 3400 cm⁻¹ (OH) and 1298 cm⁻¹ (aromatic C-H stretching frequency). The UV spectrum showed maximum absorptions at 241 nm and 304 nm character-

istic of an aromatic nucleus and a conjugated ketone, respectively [27]. ^1H NMR (Table 2) spectrum showed the presence of a tetra-substituted benzene ring with a *para* oriented singlet protons at δ_{H} 6.82 (1H, s) and 7.61 (1H, s), two methoxy protons and five aliphatic methyl protons. In support of the data hitherto ^{13}C DEPT-135 spectra showing seven methyls, eight methylenes, four methine and eleven quaternary carbons confirmed a 6-oxophenolic triterpenoid skeleton [28]. A singlet at δ_{H} 7.61 (H-4) showed HMBC (3J correlation) with keto carbon at δ_{C} 201.2 (C-6), confirmed the α, β - unsaturation indicated by the IR spectrum. One methoxy proton [δ_{H} 3.87 (3H, s)] showed a correlation with an aromatic carbon at δ_{C} 152.8 (C-3) indicating connectivity to the aromatic moiety whereas the other methoxy protons attached on carbon at δ_{C} 51.5 showed a correlation with a carboxyl carbon at δ_{C} 179.4, indicating the presence of a carboxymethyl esters (O=COCH₃). The carboxyl ester placement was confirmed by the HMBC correlation (Fig. 3) between the methyl proton (H-27) and the carbonyl carbon, which in turn showed 3J correlation with two sets of methylene protons δ_{H} 1.46/1.58 (both s) and 1.47/1.58 (both s) (H-19 and H-21, respectively). The complete connectivity of the functional groups supported by the literature data, confirmed 2-Methoxy-4-decarboxydidydrozylasterone (3) as a new compound a derivative of zylasterone isolated from *Gymnosporia blaphorodes* and *Kokoona zeylanica* [27].

3.1. Cyclooxygenase inhibitory activities

Previous anti-inflammatory studies using extracts of *G. heterophylla*




Fig. 3. Main ^1H - ^{13}C long-range correlation HMBC (\rightarrow) and ^1H - ^1H correlation COSY ($-$) for compounds 2 and 3.

showed up of 51% reduction of paw oedema [10] that was very comparable to indomethacin (positive control) pointing to the potential anti-inflammatory principles which the current study has thus far established (Table 4) using cyclooxygenase-1 and 2 (COX-1 and -2) inhibitory activity. Except for 3-Hydroxycampane (7) and lupeol (9), nine of the pure isolates showed varied COX inhibition in the functional assay (Table 3). At concentration of 10 mM dihydro- β -agarofuran sesquiterpene alkaloids 1, 2 and the triterpenoids 2–10 showed significant COX inhibition compared to the respective controls (Aspirin and Celecoxib). However, only (1), (2), (5), (6), (9), and (10) selectively inhibited COX-2 with selectivity index > 1 (Table 3) based on Griswold and Adams [29] model. The results of this study confirmed the previously reported anti-inflammatory activity for maytenic and pristimerin typical compounds associated with this genus [30,31] and particularly the *in vitro* activity of the 500 μ g/ml crude extracts against COX-1 which indicated an overall anti-inflammatory potential [32]. In this study, most of the compounds may have been good inhibitors of COX-2, but still showed COX-1 inhibitions thus may lead to many unwanted side effects. Most compounds with no carboxyl presented better COX-2 selectivity index as would be noticed for lup-20(29)-ene-1 β ,3 β -diol (6) (SI 2.22) showing comparable selectivity index to NSAIDs (non-selective COX inhibitors) [33]. Most NSAIDs show different effects against COX-1 compared with COX-2, such that low potency against COX-1 compared to COX-2 imply a lower selectivity index and such compounds from *G. heterophylla* would be suggested as good anti-inflammatory activity with reduced side effects on the stomach and kidney [33,34].

4. Conclusion

In conclusion, the study confirmed the presence anti-inflammatory principles from *G. heterophylla* which was in support of the previously established anti-inflammatory activities of the crude extracts of the same plant aerial parts. The results indicated that dihydro- β -agarofuran sesquiterpene alkaloids, triterpenoids are the major anti-inflammatory compounds from the extracts of *G. heterophylla* aerial parts. Such results are important towards development of complementary management alternatives of inflammatory reactions and other disorders besides establishment of the botanical potentials for the traditionally used plant.

Declaration of interest

The authors have declared that there is no conflict of interest.

Acknowledgement

The study was supported by Fund from National Commission for Science, Technology and Innovation Council (NACOSTI/RCD/ST&I/7th CALL/MS/001). Authors are grateful to Dr. Heiko Schuster of Georg-August University Goettingen for recording IR, NMR and Mass spectrometry data were performed and Mr. Mathenge (retired Taxonomist from University of Nairobi) identification and authentication of the plant material.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.fitote.2017.04.015>.

References

- [1] T.K. Kvien, Epidemiology and burden of illness of rheumatoid arthritis, *Pharmacoeconomics* 22 (2004) 1–12.
- [2] R.X. Zhang, A.Y. Fan, A.N. Zhou, K.D. Moudgil, Z.Z. Ma, D.Y. Lee, H.H. Fong, B.M. Berman, L. Lao, Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats, *J. Ethnopharmacol.* 121 (2009) 366–371.
- [3] P.M. Barnes, E. Powell-Griner, K. McFann, R.L. Nahin, Complementary and alternative medicine use among adults: United States, 2002, *Adv. Data* 343 (2004) 1–19.
- [4] F.A. Flores, Advances in economic botany. in: G.T. Prance, J.A. Kallunki (Eds.), *Ethnobotany in the New Tropics*, The New York Botanical Garden, Bronx, New York, 1984, pp. 1–8.
- [5] S.F. de Andrade, M. Lemos, E. Comunello, V. Noldin, F. DelleMonache, V. Chechin-Filho, R. Niero, Antiulcerogenic activity of fractions and 3,15-dioxo-21-hydroxyfriedelane isolated from *Maytenus robusta* (Celastraceae), *Arch. Pharm. Res.* 31 (2008) 41–46.
- [6] V.L. Santos, V.B.M. Costa, M.F. Agra, B.A. Silva, L.M. Batista, Pharmacological studies of ethanolic extract of *Maytenus rigida* Mar. (Celastraceae) in animal models, *Braz. J. Pharmacogn.* 17 (2007) 336–342.
- [7] A.G. González, N.L. Alvarenga, A.G. Ravelo, I.L. Bazzocchi, E.A. Ferro, A.G. Navarro, L.M. Moujir, Scutone, a new bioactive norquinonemethide triterpene from *Maytenus scutioides* (Celastraceae), *Bioorg. Med. Chem.* 4 (1996) 815–820.
- [8] A.G. González, B.M. Tincusi, S.L. Bazzocchi, J. Tokuda, H. Nishino, T. Konoshima, A.G. Ravelo, Anti-tumor promoting effects of sesquiterpenes from *Maytenus cuzcoina* (Celastraceae), *Bioorg. Med. Chem.* 8 (2000) 1773–1778.
- [9] A. Maroyi, Traditional use of medicinal plants in south-central Zimbabwe: review and perspectives, *J. Ethnobiol. Ethnomed.* 9 (2013) 1–18.
- [10] G. da Silva, M. Tanica, J. Rocha, R. Serrano, E.T. Gomes, B. Sepodes, O. Silva, *In vivo* anti-inflammatory effect and toxicological screening of *Maytenus heterophylla* and *Maytenus senegalensis* extracts, *Hum. Exp. Toxicol.* 30 (2010) 693–700.
- [11] C.N. Muthaura, G.M. Rukunga, S.C. Chhabra, G.M. Mungai, E.N.M. Njagi, Traditional phytotherapy of some remedies used in treatment of malaria in Meru district of Kenya, *S. Afr. J. Bot.* 73 (2007) 402–411.
- [12] S.V. Okello, R.O. Nyunjia, G.W. Netondo, J.C. Onyango, Ethnobotanical study of medicinal plants used by Sabaot of Mt. Elgon Kenya, *Afr. J. Tradit. Complement. Altern. Med.* 7 (2010) 1–10.
- [13] J.M. Watt, M.G. Breyer-Brandwijk, *The Medicinal and Poisonous Plants of Southern and Eastern Africa*, E & S Livingstone Ltd, Edinburgh and London, 1962.
- [14] W. Wanzala, W. Takken, W.R. Mukabana, A.O. Pala, A. Hassanali, Ethnobotanical knowledge of Bukusu community on livestock tick prevention and control in Bungoma district, western Kenya, *J. Ethnopharmacol.* 140 (2012) 298–324.
- [15] K.Y. Orabi, S.I. Al-Qasoumi, J.S. El-Olemy, I. Muhammad, Dihydroagarofuran alkaloid and triterpenes from *Maytenus heterophylla* and *Maytenus arbutifolia*, *Phytochemistry* 58 (2001) 475–480.
- [16] T. Murayama, Y. Eizuru, R. Yamada, H. Sadanari, K. Matsubara, G.M. Rukunga, M. Kofi-Tsekpo, Anticytomegalovirus activity of pristimerin, a triterpenoid quinone methide isolated from *Maytenus heterophylla* (Eckl. & Zeyh.), *Antivir. Chem. Methother.* 18 (2007) 133–139.
- [17] H. Duan, K. Kawazoe, Y. Takaishi, Sesquiterpene alkaloids from *Tripterygium hypoglaucum*, *Phytochemistry* 45 (1997) 617–621.
- [18] M.M. Pravat, A. Sree, D. Bandita, P. Mallika, K.P. Susanta, Isolation of a deoxy lupane triterpene carboxylic acid from *Finlaysonia obovata* (a mangrove plant), *Fitoterapia* 81 (2010) 977–981.
- [19] G. Savona, M. Bruno, B. Rodriguez, J.L. Marco, Triterpenoids from *Salvia deserta*, *Phytochemistry* 26 (1987) 3305–3308.
- [20] Y.-L. Li, J.-G. Zhang, P. Yu, B.-L. Ke, J. Ye, X.-W. Yang, H.-Z. Jin, W.-D. Zhang, New monoterpenes, diterpenes, and lignin from *Abies recurvata*, *Planta Med.* 78 (2012) 1574–1578.
- [21] G.F. Sousa, L.P. Duarte, A.F.C. Alcantara, G.D.F. Silva, A.S. Vieira-Filho, R.R. Silva, S.A. Vieira-Filho, R.R. Silva, D.M. Oliveira, J.A. Takahashi, New triterpenes from *Maytenus robusta*: structural elucidation based on NMR experimental data and theoretical calculations, *Molecules* 17 (2012) 13439–13456.
- [22] S.M. Abdullahi, A.M. Musa, M.I. Abdullahi, M.I. Sule, Y.M. Sani, Isolation of Lupeol from the stem bark of *Lonchocarpus sericeus* (Papilionaceae), *Sch. Acad. J. Biosci.* 1 (2013) 18–19.
- [23] J. Fotie, D.S. Bohle, M.L. Leimanis, E. Georges, C. Rukungu, A.E. Nkengfack, Lupeol, long-chain fatty esters with antimalarial activity from *Holarrhena floribunda*, *J. Nat. Prod.* 69 (2006) 62–67.
- [24] K.P. Lutta, C. Bii, A.T. Akenga, W.W. Cornelius, Antimicrobial marine natural products from the sponge *Axinella infundibuliformis*, *Rec. Nat. Prod.* 2 (2008) 116–127.
- [25] S.E. Kim, Y.H. Kim, J.J. Lee, A New sesquiterpene ester from *Celastrus orbiculatus* reversing multidrug resistance in cancer cells, *J. Nat. Prod.* 61 (1998) 108–111.
- [26] P.V. Kiem, C.V. Minh, H.T. Huong, N.H. Nam, J.J. Lee, Y.H. Kim, Pentacyclic triterpenoids from *Mallotus apelta*, *Arch. Pharm. Res.* 27 (2004) 1109–1113.
- [27] G.M. Kamal, B. Gunaherath, A.A. Gunatilaka, Studies on terpenoids and steroids. Part 3. Structure and synthesis of a new phenolic D: A-friedo-24-noroleanane triterpenoid, zylasterone, from *kokoona zeylanica*, *J. Chem. Soc. Perkin Trans. 1* (1983) 2845–2850.
- [28] H. Itokawa, O. Shiota, H. Ikuta, H. Morita, K. Takeya, Y. Itaka, Triterpene from *Maytenus ilicifolia*, *Phytochemistry* 30 (1991) 3713–3716.
- [29] D.E. Griswold, J.L. Adams, Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date, *Med. Res. Rev.* 16 (1996) 181–206.
- [30] V.M. Dirsch, A.K. Kiemer, H. Wagner, W.A.M. Vollmar, The triterpenoid quinone-methide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages, *Eur. J. Pharmacol.* 336 (1997) 211–217.
- [31] S. Sosa, C.F. Morelli, A. Tubaro, P. Cairoli, G. Speranza, P. Manitto, Anti-inflammatory activity of *Maytenus senegalensis* root extracts and of maytenoic acid, *Phytomedicine* 14 (2007) 109–114.
- [32] E.N. Matu, J. van Staden, Antibacterial and anti-inflammatory activities of some

- plants used for medicinal purposes in Kenya, *J. Ethnopharmacol.* 87 (2003) 35–41.
- [33] R.M. Botting, Inhibitors of cyclooxygenase: mechanism, selectivity and uses, *J. Physiol. Pharmacol.* 57 (2006) 113–124.
- [34] M. Pairet, L. Churchill, G. Trummlitz, G. Engelhardt, Differential inhibition of cyclooxygenase-1 (COX-1) and -2 (COX-2) by NSAIDs: consequences on anti-inflammatory activity versus gastric and renal safety, *Inflamm. Pharmacol.* 4 (1996) 61–70.